Mara Goldstein
Stock Analyst at Mizuho
(2.74)
# 1,995
Out of 4,918 analysts
77
Total ratings
44.83%
Success rate
6.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Maintains: Outperform | $32 → $30 | $5.99 | +400.83% | 3 | May 19, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $30 → $10 | $2.68 | +273.83% | 5 | May 12, 2025 | |
| VSTM Verastem | Maintains: Outperform | $9 → $8 | $6.27 | +27.59% | 7 | Apr 9, 2025 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $9.01 | +366.15% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $8.02 | +523.44% | 2 | Jan 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $45 | $9.90 | +354.55% | 1 | Dec 22, 2023 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $75.09 | +2.54% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $1.43 | +391.23% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $1.08 | +644.19% | 5 | Nov 20, 2023 | |
| LPTX Leap Therapeutics | Maintains: Buy | $20 → $12 | $0.30 | +3,855.17% | 5 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $90 | $22.70 | +296.48% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $4.01 | -12.72% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $2.10 | +17,042.86% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $3.37 | +493.47% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $79.22 | +64.10% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $2.33 | -14.16% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $2.31 | +419.48% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $9 | $0.08 | +11,121.95% | 3 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $36.83 | -45.70% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $6.11 | +686.24% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $22.17 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $4.34 | +222.95% | 1 | Oct 12, 2017 |
Kura Oncology
May 19, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $5.99
Upside: +400.83%
Iovance Biotherapeutics
May 12, 2025
Maintains: Outperform
Price Target: $30 → $10
Current: $2.68
Upside: +273.83%
Verastem
Apr 9, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $6.27
Upside: +27.59%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $9.01
Upside: +366.15%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $8.02
Upside: +523.44%
Syndax Pharmaceuticals
Dec 22, 2023
Initiates: Buy
Price Target: $45
Current: $9.90
Upside: +354.55%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $75.09
Upside: +2.54%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $1.43
Upside: +391.23%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $1.08
Upside: +644.19%
Leap Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $20 → $12
Current: $0.30
Upside: +3,855.17%
Aug 7, 2023
Reiterates: Neutral
Price Target: $90
Current: $22.70
Upside: +296.48%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $4.01
Upside: -12.72%
Apr 24, 2023
Reiterates: Buy
Price Target: $360
Current: $2.10
Upside: +17,042.86%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $3.37
Upside: +493.47%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $79.22
Upside: +64.10%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $2.33
Upside: -14.16%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $2.31
Upside: +419.48%
Nov 9, 2022
Upgrades: Buy
Price Target: $9
Current: $0.08
Upside: +11,121.95%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $36.83
Upside: -45.70%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $6.11
Upside: +686.24%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $22.17
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $4.34
Upside: +222.95%